- Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Stohl, W., Hiepe, F., Latinis, K.M., Thomas, M., Scheinberg, M.A., Clarke, A., Aranow, C., Wellborne, F.R., Abud-Mendoza, C., Hough, D.R., Pineda, L., Migone, T.S., Zhong, Z.J., Freimuth, W.W., Chatham, W.W. Arthritis Rheum. (2012)